Enzon Names Dr. Ivan Horak Chief Scientific Officer.BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the appointment of Ivan Horak, M.D. to the position of Executive Vice President of Research and Development and Chief Scientific Officer. In his new position Dr. Horak will oversee all aspects of Enzon's research and development, regulatory affairs, and quality assurance activities. Dr. Horak brings an impressive background in drug development to Enzon and is a board certified board certified, adj the status of a dental specialist such as an orthodontist who has become a board diplomate by successfully completing the certification program of the recognized certification board in that area of practice. medical oncologist medical oncologist Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists. . He has held a number of senior medical and scientific positions in the pharmaceutical industry, as well as the National Cancer Institute (NCI See Liberate. ). "The addition of Dr. Horak to our executive management team further strengthens the pharmaceutical expertise at Enzon. Dr Horak will be instrumental in enhancing the productivity of our R&D pipeline," said Jeffrey H. Buchalter, Enzon's chairman and chief executive officer. "I have known Dr. Horak professionally for many years and have full confidence his continued leadership within the oncology community will contribute greatly to our long-term success in this therapeutic area." Dr. Horak joins Enzon from Immunomedics, Inc. (Nasdaq: IMMU IMMU Independent Munitions Maintenance Unit ), where he served as Chief Scientific Officer since July 2003 and Executive Vice President of Research and Development since May 2002. Before joining Immunomedics, Dr. Horak was employed by Pharmacia as a Vice President for Clinical Oncology, where he helped direct the global development of oncology compounds from 1999 to 2002, including Camptosar(R) for metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. . From 1996 to 1999, Dr. Horak held a variety of clinical research positions at Janssen Research Foundation, a subsidiary of the Johnson & Johnson Company, including International Director for Clinical Research and Development, Oncology. Prior to joining Janssen, Dr. Horak spent nine years at the NCI where he most recently served as a cancer expert for the Metabolism Branch. In addition to over 50 scientific publications, Dr. Horak is a member of several prominent medical societies and has served on various committees for the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational and the International Union Against Cancer. He also serves on the editorial board of the prestigious journal, Cancer Research. About Enzon Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular mac·ro·mol·e·cule n. A very large molecule, such as a polymer or protein, consisting of many smaller structural units linked together. Also called supermolecule. engineering technology platforms, including PEG modification and single-chain antibody (SCA (Single Connector Attachment) An 80-pin plug and socket used to connect peripherals. With a SCSI drive, it rolls three cables (power, data channel and ID configuration) into one connector for fast installation and removal. (R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Further information about Enzon can be found on the Company's web site at www.enzon.com. All information in this press release is as of September 6, 2005 and the Company undertakes no duty to update this information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion